SFN can upregulate ROS production and Nrf2 activity, and TRAIL significantly enhances SFN-mediated ROS production, which leads to the apoptosis of TRAIL-resistant bladder cancer cells. The gene discussed is TNFSF10; the disease is urinary bladder carcinoma.